Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 56(12): 5094-114, 2013 Jun 27.
Article in English | MEDLINE | ID: mdl-23678871

ABSTRACT

The apical sodium-dependent bile acid transporter (ASBT) transports bile salts from the lumen of the gastrointestinal (GI) tract to the liver via the portal vein. Multiple pharmaceutical companies have exploited the physiological link between ASBT and hepatic cholesterol metabolism, which led to the clinical investigation of ASBT inhibitors as lipid-lowering agents. While modest lipid effects were demonstrated, the potential utility of ASBT inhibitors for treatment of type 2 diabetes has been relatively unexplored. We initiated a lead optimization effort that focused on the identification of a potent, nonabsorbable ASBT inhibitor starting from the first-generation inhibitor 264W94 (1). Extensive SAR studies culminated in the discovery of GSK2330672 (56) as a highly potent, nonabsorbable ASBT inhibitor which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Drug Discovery , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Methylamines/chemistry , Methylamines/pharmacology , Organic Anion Transporters, Sodium-Dependent/antagonists & inhibitors , Symporters/antagonists & inhibitors , Thiazepines/chemistry , Thiazepines/pharmacology , Animals , Bile Acids and Salts/metabolism , Dogs , Drug Stability , HEK293 Cells , Humans , Hypoglycemic Agents/metabolism , Hypoglycemic Agents/therapeutic use , Male , Methylamines/metabolism , Methylamines/therapeutic use , Mice , Rats , Solubility , Thiazepines/metabolism , Thiazepines/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...